Cara Placing Korsuva Hopes On Oral Formulation, Broad Pruritus Label
Executive Summary
I.V. Korsuva now has an August FDA action date, which partner Vifor would commercialize in the ESRD dialysis setting while Cara works toward a broad anti-pruritus label for its oral tablet formulation.